(Q40550719)

21 September 2017

1 reference

title

Third-generation cephalosporins (English)

1 reference

21 September 2017

Klein NC

1

1 reference

21 September 2017

Cunha BA

series ordinal

2

1 reference

21 September 2017

publication date

1 July 1995

1 reference

Medical Clinics of North America

21 September 2017

published in

1 reference

21 September 2017

volume

79

1 reference

21 September 2017

issue

4

1 reference

21 September 2017

page(s)

705-719

1 reference

Comparison of the efficacy and safety of ceftriaxone to ampicillin/ chloramphenicol in the treatment of childhood meningitis

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Safety of parenteral third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Management of infections caused by antibiotic-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

1 reference

7 January 2021

Cephalosporin antimicrobial agents and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Ceftriaxone-associated cholecystitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Cefoperazone in the treatment of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Role of ceftriaxone in sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Comparative toxicities of third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

The new beta-lactamase-stable cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Cephalosporins in the treatment of meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Treatment of bacterial meningitis with ceftizoxime

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Potential for bleeding with the new beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Reversible ceftriaxone-associated biliary pseudolithiasis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

Clinical pharmacokinetics of ceftriaxone

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930034-7

7 January 2021

10.1016/S0025-7125(16)30034-7

Identifiers

DOI

0 references

1 reference